injection site reactionlong-acting therapyrilpivirineBACKGROUND. Cabotegravir (CAB) + rilpivirine (RPV) dosed monthly or every 2 months is a complete long-acting (LA) regimen for the maintenance of human immunodeficiency virus type 1 virologic suppression. Across the phase 3/3b trials, the most ...
Pain, tenderness, hardened mass or lump, swelling, bruising, redness, itching, warmth, loss of sensation at the injection site, abscess, and discoloration; diarrhea; headache; fever; tiredness; sleep problems; nausea; dizziness; passing gas; stomach pain; vomiting; muscle pain; rash; loss of ...
Pain, tenderness, hardened mass or lump, swelling, bruising, redness, itching, warmth, loss of sensation at the injection site, abscess, and discoloration; diarrhea; headache; fever; tiredness; sleep problems; nausea; dizziness; passing gas; stomach pain; vomiting; muscle pain; rash; loss of ...
rectal, vaginal, penile, and intravenous virus exposures8,9,10,11,12. In Phase 2a/b studies, CAB LA was generally safe and well tolerated with injection site reactions that were mild or moderate as the most common adverse events4,13. Two large randomized clinical trials (HPTN 083 and 084...
Administer cabotegravir extended-release suspension by gluteal IM injection.Ventrogluteal site is recommended; however, a dorsolateral approach is acceptable.Consider BMI of the patient to ensure appropriate needle length to reach gluteus muscle.Longer needle lengths may be required for patients with high...
All participants who received SC doses of CAB-ULA reported injection site reactions (ISRs), while 22/32 who received IM doses reported ISR events. The majority of IM ISRs were mild pain (grade 1) that lasted...
(n=1). The Grade 3 adverse reaction of drug hypersensitivity led to discontinuation of rilpivirine during oral lead-in. Sixty-two percent of patients who received at least one injection of cabotegravir or rilp...
Thus, NM2CAB would require a 1 ml injection volume for yearly dosing when compared to a 2 ml monthly injection for CAB LA. In addition, no injection site reactions were observed. Thus, NM2CAB provides an improvement over the current approved CAB LA with an extended dosing interval, ...
The most common adverse reactions (Grades 1 to 4) observed in ≥2% of participants receiving long-acting cabotegravir and rilpivirine were injection site reactions, pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash. In ATLAS-2M, ...
Long-acting cabotegravir was found to be superior to daily oral FTC/TDF in preventing HIV acquisition in the trial population. The most common adverse reactions (all grades) observed in at least 1% of subjects receiving long-acting cabotegravir were injection site reactions, diarrhoea, headache,...